ArticleBlood2006
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 93 citations in OpenAlex.
- New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies.Frontiers in immunology · 2025Review
- Choosing T-cell sources determines CAR-T cell activity in neuroblastoma.Frontiers in immunology · 2024Article
- Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells.Cancer gene therapy · 2022Article
- Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.Cancers · 2022Article
- Efficient lentiviral transduction method to gene modify cord blood CD8Molecular therapy. Methods & clinical development · 2021Article
- Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies.F1000Research · 2020Review
- Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.Frontiers in immunology · 2020Review
- Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.Blood advances · 2019Article
- DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.Nature communications · 2018Article
- Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Molecular therapy. Methods & clinical development · 2017Article
- Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.Molecular imaging and biology · 2016Article
- Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Leukemia · 2015Article
- Concise review: umbilical cord blood transplantation: past, present, and future.Stem cells translational medicine · 2014Review
- A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.Immunological reviews · 2014Review
- Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.Gene therapy · 2013Article
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.Nature reviews. Clinical oncology · 2013Review
- Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Neoplasia (New York, N.Y.) · 2013Article
- Genetically engineered T cells for the treatment of cancer.Journal of internal medicine · 2013Review
- Sleeping beauty system to redirect T-cell specificity for human applications.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Disease relapse is a barrier to achieving therapeutic success after unrelated umbilical cord-blood transplantation (UCBT) for B-lineage acute lymphoblastic leukemia (B-ALL). While adoptive transfer of donor-derived tumor-specific T cells is a conceptually attractive approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive umbilical cord-blood (UCB)-derived T cells. Therefore, to generate T cells that recognize B-ALL, we have developed a chimeric immunoreceptor to redirect the specificity of T cells for CD19, a B-lineage antigen, and expressed this transgene in UCB-derived T cells. An ex vivo process, which is compliant with current good manufacturing practice for T-cell trials, has been developed to genetically modify and numerically expand UCB-derived T cells into CD19-specific effector cells. These are capable of CD19-restricted cytokine production and cytolysis in vitro, as well as mediating regression of CD19+ tumor and being selectively eliminated in vivo. Moreover, time-lapse microscopy of the genetically modified T-cell clones revealed an ability to lyse CD19+ tumor cells specifically and repetitively. These data provide the rationale for infusing UCB-derived CD19-specific T cells after UCBT to reduce the incidence of CD19+ B-ALL relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.